1. Scrip
  2. >>Focus On Asia

Japan Grants Global First Nod For Brodalumab, For Psoriasis

 
• By Ian Haydock

Japan has granted the first approval worldwide for brodalumab as a biologic therapy for psoriasis, one of two new antibodies for the disorder in a new batch of approvals that also includes Praluent and Kyprolis.

Japan's regulatory authorities have granted final approval to a group of new drugs including Kyowa Hakko Kirin Co. Ltd.'s (KHK) biologic Lumicef (brodalumab), which has received its first clearance worldwide for a range of psoriatic conditions.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.